MedX Health Corp. appoints Lesley Bourget as Chief Financial Officer


MISSISSAUGA, Ontario – (COMMERCIAL THREAD) –MedX Health Corp. (“MedX” or the “Company”) (TSXV: MDX) is pleased to announce that seasoned pharmaceutical finance executive Lesley Bourget has been appointed the Company’s Chief Financial Officer (“CFO”), effective November 8.e, 2021.

With over 30 years of experience in the healthcare, pharmaceutical and CPG industries, Ms. Bourget has a proven track record of profit generation by successfully leading product portfolio optimization efforts, negotiating acquisitions. on a large scale and by designing and implementing mergers in R&D. space out. Ms. Bourget most recently served as CFO of Aspen Pharmacare Canada, where she was instrumental in achieving record profit levels for the company and in optimizing inventory and wholesale processes. Ms. Bourget’s appointment will further support MedX’s global commercialization strategy, as the Company seeks to build on the momentum of ongoing commercial and product distribution pilot projects in North America and Europe, with other pilots planned in the coming months.

Ms. Bourget holds the professional designation of Certified Management Accountant (CPA, CMA) and is qualified in international financial reporting thanks to an IFRS certification (CMA).

“On behalf of the board of directors and management team of MedX, I extend a warm welcome to Lesley as she assumes the central role of CFO during a period of rapid growth for our company,” said Sylvain Desjeans, President and CEO of MedX. “Lesley is an inspiring and visionary leader, with a long track record of supporting market growth through her extensive experience negotiating mergers and acquisitions and building alliances for pharmaceutical and public healthcare companies. I look forward to working with Lesley to further exploit MedX’s growth opportunities ahead.

On his appointment as Chief Financial Officer, Lesley Bourget said: “I was drawn to MedX because of its life-saving mission and the unique ability of its technology to make teledermatology accessible to patients around the world. Strengthening virtual health services has never been more important than it is today, in the midst of a global pandemic. I feel privileged to join the MedX team to help them realize their growth potential and improve patient outcomes.

Teledermatology is a subspecialty of dermatology that provides safe and effective virtual care – both screening and assessing patients – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s leading telemedicine platform enables healthcare professionals to quickly and accurately assess suspicious moles, lesions, and other skin conditions through its skin capture technology. ‘images, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process.

MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface. MedX’s DermSecure® screening platform then transmits these high-resolution images securely for virtual dermatological evaluation by a certified dermatologist in just 72 hours, against a wait time of up to 90 days for a dermatological evaluation. traditional.

About MedX:

MedX, headquartered in Ontario, Canada, is a leading skin health-focused medical device and software company with its SIAscopy® telemedicine platform on DermSecure®, using its SIAscopy® technology. SIAscopy® is also integrated into its SIAMETRICS®, SIMSYS® and MoleMate® products, which MedX manufactures in its ISO 13485 certified factory. SIAMETRICS®, SIMSYS® and MoleMate® include hand-held devices that use patented technology using light and its transfer to view up to 2mm below moles and suspicious lesions in a painless and non-invasive way, with its software then creating real-time images allowing doctors and dermatologists to assess all types of moles or lesions within seconds. These products are approved by Health Canada, the United States Food and Drug Administration, the Therapeutic Goods Administration and European Conformity for use in Canada, United States, Australia, New Zealand, European Union , Brazil and Turkey. Visit

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties.


Leave A Reply